EBAG9 and endometrial cancer: In 48 patients with endometrial cancer, 16, 14, 12, and 6 cases showed no expression, 1+, 2+, and 3+, respectively, for RCAS1, while for ADAM9, 6, 9, 14, and 19 cases had no expression, 1+, 2+, and 3+, respectively.